In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...

Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...

Chief Executive Richard Francis said Wednesday as Teva stock plummeted on its light earnings outlook. For the year, the pharma behemoth expects to earn an adjusted $2.35 to $2.65 per share.

Shares of Teva Pharmaceutical Industries ( TEVA -2.29%) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p.m. ET. The leg down comes as the S&P 500 ( ^GSPC -0.01%) and Nasdaq ...

Teva Pharmaceutical Industries' Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. Management's cautious 2025 guidance sets a low bar, likely to be ...

Teva currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. Each was handpicked by a Zacks expert as the #1 favorite stock to ...

On February 18, 2025, Teva Pharmaceutical Industries Limited (NYSE:TEVA) stock closed at $16.57 per share with a market capitalization of $19.17 billion. Sound Shore Management stated the ...

Lekha Gupta Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025' Axsome settles Auvelity patent litigation with ...